| HOME >> MEDICINE >> TECHNOLOGY |
Poster Presented at the 2008 AACR Annual Meeting
SOMERSET, N.J., April 14 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that Dr. Intae Lee with the University of Pennsylvania has reported that Alfacell's ONCONASE (ranpirnase) could be a promising radiation sensitizer for lung cancer treatment. Dr. Lee presented the pre-clinical in vivo and in vitro data in a poster at the 2008 American Association of Cancer Research (AACR) Annual Meeting being held April 12 - 16 in San Diego.
In the poster titled "The inhibition of radiation repair by ranpirnase +/- I-buthionine sulfoximide on lung cancer," Dr. Lee provided pre-clinical evidence that ONCONASE +/- I-buthionine sulfoximide significantly increased the radiation-induced growth delay of lung tumors in vivo without increases in skin reaction, compared to radiation alone. Additionally, in vivo and in vitro data presented indicated that ONCONASE significantly increased apoptosis (programmed cell death) in several human non-small cell lung cancer (NSCLC) cell lines (A549, NCI-H1975 and HOP-62). Dr. Lee and his team of researchers also showed that the radiation repair mechanisms known as sub-lethal damage repair (SLDR) and potentially lethal damage repair (PLDR), which lead to radiation resistance in tumors, were significantly inhibited by ONCONASE in vitro.
"Our research suggests potential utility of ONCONASE as a radiotherapy enhancer for the treatment of NSCLC patients," said Dr. Lee. "It is important to overcome PLDR as it can ultimately lead to radiation resistance. One of our key findings is the inhibiting impact of ONCONASE on the PLDR mechanism, which is a pre-requisite to developing a radiotherapy enhancer."
Kuslima Shogen, Alfacell's chief executive officer, added: "This work by Dr. Lee and his team provides further evidence of the potential for ONCONASE to mitigate the resistance that often develops in, and confounds the treatment of NSCLC."
About ONCONASE(R)
ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.
About Alfacell Corporation
Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.
Safe Harbor
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe,"
"estimate," "project," "expect" or similar expressions. Forward-looking
statements involve risks and uncertainties that could cause actual results
to differ materially from the forward-looking statements. Factors that
would cause or contribute to such differences include, but are not limited
to, uncertainties involved in transitioning from concept to product,
uncertainties involving the ability of the company to finance research and
development activities, potential challenges to or violations of patents,
uncertainties regarding the outcome of clinical trials, the company's
ability to secure necessary approvals from regulatory agencies, dependence
upon third-party vendors, and other risks discussed in the company's
periodic filings with the Securities and Exchange Commission. By making
these forward-looking statements, the company undertakes no obligation to
update these statements for revisions or changes after the date of this
release.
Media Contact: Investor Contact:
David Schull or Wendy Lau Timothy Engel
Russo Partners Russo Partners
212-845-4271 212-845-4242
David.Schull@russopartnersllc.com Timothy.Engel@russopartnersllc.com
Wendy.Lau@russopartnersllc.com
'/>"/>
| SOURCE Alfacell Corporation Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
4. Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
5. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
6. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
7. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
8. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
11. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |